% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Moretti:282594,
      author       = {Moretti, Davide Vito and Kuhn, Elizabeth and Dubbelman,
                      Mark and Sam, Sikkes and Raphael Machado, Castilhos and
                      Chapman, Silvia and Gifford, Katie and Butterbrod, Elke and
                      Nosheny, Rachel},
      title        = {{C}linical definition, biological characterization, and
                      detection guidelines of subjective cognitive decline due to
                      {A}lzheimer's disease and related dementia: {A} position
                      paper from {ISTAART} {SCD} {PIA}},
      journal      = {Alzheimer's and dementia},
      volume       = {21},
      number       = {12},
      issn         = {1552-5260},
      address      = {Hoboken, NJ},
      publisher    = {Wiley},
      reportid     = {DZNE-2025-01352},
      pages        = {e70847},
      year         = {2025},
      abstract     = {Subjective cognitive decline (SCD)—self-perceived
                      cognitive worsening without objective deficits—has emerged
                      as a clinically meaningful, potential early manifestation of
                      Alzheimer's disease (AD). Positioned at the intersection of
                      normal aging, neuropsychiatric symptoms, and preclinical
                      neurodegeneration, SCD offers a unique window for early
                      detection and intervention. However, detection
                      heterogeneity, variable prognostic trajectories, and limited
                      equity in assessment hinder its full clinical utility. This
                      position paper synthesizes current evidence on SCD's
                      diagnostic complexity, neurobiological underpinnings, and
                      modifiable influences. We highlight the need for harmonized
                      assessment frameworks, scalable digital tools, inclusive
                      research, and ethically grounded biomarker disclosure
                      practices. Importantly, we advocate for personalized,
                      (non-)pharmacological interventions targeting this early
                      phase. By refining the conceptualization and
                      operationalization of SCD, we can better identify
                      individuals at heightened AD risk and deliver timely,
                      equitable, and meaningful prevention strategies. SCD
                      represents a pivotal inflection point in the dementia
                      continuum—and a call to shift toward proactive brain
                      health.},
      subtyp        = {Review Article},
      cin          = {AG Wagner},
      ddc          = {610},
      cid          = {I:(DE-2719)1011201},
      pnm          = {353 - Clinical and Health Care Research (POF4-353)},
      pid          = {G:(DE-HGF)POF4-353},
      typ          = {PUB:(DE-HGF)16},
      doi          = {10.1002/alz.70847},
      url          = {https://pub.dzne.de/record/282594},
}